{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:54:37Z","timestamp":1790610877634,"version":"4.1.0"},"reference-count":124,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Targeted therapy and immunotherapy represent major innovations in the treatment of lung cancer. However, in patients with driver gene-positive tumors, the emergence of acquired resistance to targeted drugs is inevitable. As for immunotherapy, its efficacy in early-stage lung cancer patients remains uncertain due to strong immune heterogeneity. In advanced and locally advanced patients, high tumor mutational burden leads to significant genomic instability and tumor progression, and resistance still inevitably develops even with standard chemotherapy combined with immunotherapy. Cancer vaccines, as an approach that activates the antitumor immune cycle from its origin, offer advantages such as the ability to target multiple antigens, minimal off-target effects, a wide therapeutic window, and low toxicity. Furthermore, such vaccines can induce long-lasting immune memory and possess a certain capacity to remodel the tumor immune microenvironment, which helps prevent cancer recurrence, demonstrating broad prospects in lung cancer treatment. Currently, various types of tumor vaccines (including those based on microorganisms, peptides, proteins, exosomes, and DNA) have been developed, yet they often face limitations in safety, insufficient personalization, and immature production pipelines. In contrast, messenger RNA (mRNA)-based vaccines offer distinct advantages, including the efficient generation of protective immune responses, relatively low side effects, and lower acquisition costs, making them a forefront option for novel lung cancer therapies. This review summarizes the current research status of lung cancer vaccines, clarifies the unique therapeutic advantages of mRNA vaccines compared to traditional vaccine modalities, and highlights existing challenges associated with mRNA vaccines. It also provides an overview of current clinical trials of mRNA vaccines for lung cancer and proposes rational design and clinical application strategies for personalized mRNA vaccines within the framework of precision oncology, based on evidence-based medicine.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1707654","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:15:56Z","timestamp":1770894956000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["mRNA vaccines transform personalized lung cancer treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Kaiqi","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitong","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University","place":["Xi\u2019an, China"]},{"name":"College of Life Sciences, Northwestern University","place":["Xi\u2019an, China"]},{"name":"Department of Thoracic Surgery, Air Force Medical Center, Fourth Military Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowei","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University","place":["Xi\u2019an, China"]},{"name":"Department of Thoracic Surgery, Air Force Medical Center, Fourth Military Medical University","place":["Beijing, China"]},{"name":"Department of Thoracic Surgery, 962 Hospital of the joint Logistics Support Force","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinxi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Air Force 986 Hospital","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University","place":["Xi\u2019an, China"]},{"name":"Department of Thoracic Surgery, Shaanxi Provincial People\u2019s Hospital","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbin","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, First Medical Center, Chinese People\u2018s Liberation Army (PLA) General Hospital and People\u2018s Liberation Army (PLA) Medical School","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlu","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University","place":["Xi\u2019an, China"]},{"name":"Department of Thoracic Surgery, First Medical Center, Chinese People\u2018s Liberation Army (PLA) General Hospital and People\u2018s Liberation Army (PLA) Medical School","place":["Beijing, China"]},{"name":"Innovation Center for Advanced Medicine, Tangdu Hospital, Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.750657","article-title":"Immunotherapy in non-small cell lung cancer with actionable mutations other than EGFR","volume":"11","author":"Seegobin","year":"2021","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4149\/302_151001N511","article-title":"A new hope: the immunotherapy in small cell lung cancer","volume":"63","author":"Li","year":"2016","journal-title":"Neoplasma"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.03.15","article-title":"Updated statistics of lung and bronchus cancer in United States (2018)","volume":"10","author":"Boloker","year":"2018","journal-title":"J Thorac Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.823618","article-title":"Immunotherapy in lung cancer: current landscape and future directions","volume":"13","author":"Mamdani","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.526","article-title":"Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor","volume":"29","author":"Ercan","year":"2010","journal-title":"Oncogene"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1753465815587820","article-title":"Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance","volume":"9","author":"Tartarone","year":"2015","journal-title":"Ther Adv Respir Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.21037\/tlcr.2017.03.01","article-title":"Current state of immunotherapy for non-small cell lung cancer","volume":"6","author":"Malhotra","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.05.003","article-title":"Cancer and the immune system: basic concepts and targets for intervention","volume":"42","author":"Pardoll","year":"2015","journal-title":"Semin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217241","article-title":"Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions","volume":"604","author":"Gang","year":"2024","journal-title":"Cancer Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.006","article-title":"ATALANTE-1 study group. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1","volume":"34","author":"Besse","year":"2023","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","article-title":"The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives","volume":"18","author":"Sun","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","article-title":"KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors","volume":"14","author":"Lu","year":"2023","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207841119","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.adr8470","article-title":"Deep generative models design mRNA sequences with enhanced translational capacity and stability","volume":"390","author":"Zhang","year":"2025","journal-title":"Science"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-SITC2024.1486","article-title":"1486 preliminary results from LuCa-MERIT-1, a phase I trial evaluating BNT116, a fixed antigen mRNA vaccine, plus Cemiplimab in advanced non-small cell lung Cancer after progression on PD-1 inhibition","volume-title":"Proceedings of the late-breaking","author":"Atmaca","year":"2024"},{"key":"B20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","article-title":"Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer","volume":"6","author":"Ding","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68143-9","article-title":"Smallpox","volume":"367","author":"Moore","year":"2006","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1007\/BF01248030","article-title":"The diffusion of ions from a phospholipid model membrane system","volume":"63","author":"Bangham","year":"1967","journal-title":"Protoplasma"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1096\/fj.10-0503","article-title":"From \u201cbanghasomes\u201d to liposomes: a memoir of Alec Bangham, 1921\u20132010","volume":"24","author":"Deamer","year":"2010","journal-title":"FASEB J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197609302951406","article-title":"The carrier potential of liposomes in biology and medicine (second of two parts)","volume":"295","author":"Gregoriadis","year":"1976","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.16.6077","article-title":"Cationic liposome-mediated RNA transfection","volume":"86","author":"Malone","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1546298","article-title":"Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA","volume":"255","author":"Jirikowski","year":"1992","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2174\/0115680096360059250131075456","article-title":"Groundbreaking mRNA lung cancer vaccine trials: A new dawn in cancer treatment","volume":"25","author":"Hussain","year":"2025","journal-title":"Curr Cancer Drug Targets"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102669","article-title":"Minimalist mRNAs: A fast track to cancer vaccines","volume":"36","author":"Salaberry","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004746","article-title":"An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs","volume":"10","author":"Schnee","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines4040039","article-title":"Replicon RNA viral vectors as vaccines","volume":"4","author":"Lundstrom","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.060","article-title":"The advent of clinical self-amplifying RNA vaccines","volume":"33","author":"Casmil","year":"2025","journal-title":"Mol Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","article-title":"mRNA vaccine: a potential therapeutic strategy","volume":"20","author":"Wang","year":"2021","journal-title":"Mol Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/d41591-023-00072-0","article-title":"Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00608-8","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.958043","article-title":"Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC","volume":"12","author":"Evans","year":"2022","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0855","article-title":"A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients","volume":"22","author":"Rodriguez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad8709","article-title":"From the RNA world to the clinic","volume":"352","author":"Sullenger","year":"2016","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx290","article-title":"Characterizing exogenous mRNA delivery, trafficking, cytoplasmic release and RNA-protein correlations at the level of single cells","volume":"45","author":"Kirschman","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.immuni.2021.02.014","article-title":"Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery","volume":"54","author":"Chiou","year":"2021","journal-title":"Immunity"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-011-1003-3","article-title":"Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial","volume":"137","author":"Butts","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00269","article-title":"CIMAvax-EGF: a new therapeutic vaccine for advanced non-small cell lung cancer patients","volume":"8","author":"Saavedra","year":"2017","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.198069","article-title":"Comparative analysis of adenovirus, mRNA, and protein vaccines reveals context-dependent immunogenicity and efficacy","volume":"10","author":"Awakoaiye","year":"2025","journal-title":"JCI Insight"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-1050","article-title":"Dependence on the MUC1-C oncoprotein in non\u2013small cell lung cancer cells","volume":"10","author":"Raina","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B48","unstructured":"Study details\n          \n          ClinicalTrials.gov\n          Vaccine therapy in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2821","article-title":"Phase I trial of intratumoral injection of CCL21 gene\u2013modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T-cell infiltration","volume":"23","author":"Lee","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3779\/j.issn.1009-3419.2014.01.06","article-title":"Progress in immunotherapy for non-small cell lung cancer","volume":"17","author":"Xu","year":"2014","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145130","article-title":"Self-amplifying RNA viruses as RNA vaccines","volume":"21","author":"Lundstrom","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4161\/onci.19863","article-title":"TG4010: A therapeutic vaccine against MUC1 expressing tumors","volume":"1","author":"Limacher","year":"2012","journal-title":"OncoImmunology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31817c6b4f","article-title":"A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III\/IV non-small cell lung cancer","volume":"3","author":"Ramlau","year":"2008","journal-title":"J Thorac Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.06.035","article-title":"Cancer vaccines: building a bridge over troubled waters","volume":"185","author":"Sellars","year":"2022","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.3390\/v16091404","article-title":"mRNA vaccination: an outlook on innate sensing and adaptive immune responses","volume":"16","author":"Shoja Doost","year":"2024","journal-title":"Viruses"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-04001-7","article-title":"The crosstalk between viral RNA- and DNA-sensing mechanisms","volume":"78","author":"Cai","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13080882","article-title":"Decrypting the immune symphony for RNA vaccines","volume":"13","author":"Weidensee","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/antib13010013","article-title":"SARS-coV-2: A glance at the innate immune response elicited by infection and vaccination","volume":"13","author":"Manfrini","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c09365","article-title":"mRNA-based vaccination drives in vivo dendritic cell reprogramming and selective cytotoxic T lymphocyte modulation for enhanced antitumor immunity","volume":"19","author":"Zhang","year":"2025","journal-title":"ACS Nano"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1294929","article-title":"Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design","volume":"14","author":"Clemente","year":"2023","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102405","article-title":"The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines","volume":"107","author":"Wei","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9080848","article-title":"Antigen presentation of mRNA-based and virus-vectored SARS-coV-2 vaccines","volume":"9","author":"Rijkers","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"113578","DOI":"10.1016\/j.jconrel.2025.02.074","article-title":"An mRNA vaccine encoding proteasome-targeted antigen enhances CD8+ T cell immunity","volume":"381","author":"Ling","year":"2025","journal-title":"J Control Release"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1618406","article-title":"Harnessing cellular immunity for next-generation vaccines against respiratory viruses: mechanisms, platforms, and optimization strategies","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s42399-022-01168-3","article-title":"mRNA vaccines as an efficient approach for the rapid and robust induction of host immunity against SARS-coV-2","volume":"4","author":"Noor","year":"2022","journal-title":"SN Compr Clin Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation","volume":"15","author":"Roche","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00262-025-03992-7","article-title":"Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model","volume":"74","author":"Nguyen","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2023.07.059","article-title":"Immunotherapeutic treatment of lung cancer and bone metastasis with a mPLA\/mRNA tumor vaccine","volume":"169","author":"Ma","year":"2023","journal-title":"Acta Biomater"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030397","article-title":"Identification and analysis of unstructured, linear B-cell epitopes in SARS-coV-2 virion proteins for vaccine development","volume":"8","author":"Corral-Lugo","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2024.10.013","article-title":"Challenges and considerations in multi-epitope vaccine design surrounding toll-like receptors","volume":"45","author":"Shah","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2014.67","article-title":"DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model","volume":"21","author":"Weng","year":"2014","journal-title":"Gene Ther"},{"key":"B76","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: current preclinical and clinical developments and future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B79","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: a biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B80","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-62703-260-5_2","article-title":"In vitro Transcription of long RNA Containing modified nucleosides","volume":"969","author":"Pardi","year":"2013","journal-title":"Methods Mol Biol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J Control Release"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ads1328","article-title":"An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses","volume":"10","author":"Aunins","year":"2025","journal-title":"Sci Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17435889.2025.2595118","article-title":"Targeting ligand PDL1 for cardiotoxicity assessment and cardiac protection in immune-related myocarditis","volume":"27","author":"Li","year":"2025","journal-title":"Nanomed (Lond)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mrna yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31815ce501","article-title":"Results of the first phase I\/II clinical vaccination trial with direct injection of mRNA","volume":"31","author":"Weide","year":"2008","journal-title":"J Immunother"},{"key":"B86","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-021-01348-0","article-title":"mRNA therapeutics in cancer immunotherapy","volume":"20","author":"Beck","year":"2021","journal-title":"Mol Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-021-01339-1","article-title":"Clinical and immunological effects of mRNA vaccines in Malignant diseases","volume":"20","author":"Heine","year":"2021","journal-title":"Mol Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","article-title":"Direct injection of protamine-protected mRNA: results of a phase 1\/2 vaccination trial in metastatic melanoma patients","volume":"32","author":"Weide","year":"2009","journal-title":"J Immunother"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.973712","article-title":"Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.9b00833","article-title":"Chemical strategies to boost cancer vaccines","volume":"120","author":"Li","year":"2020","journal-title":"Chem Rev"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.02.007","article-title":"Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction","volume":"46","author":"Abelin","year":"2017","journal-title":"Immunity"},{"key":"B94","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","article-title":"MHC-II neoantigens shape tumour immunity and response to immunotherapy","volume":"574","author":"Alspach","year":"2019","journal-title":"Nature"},{"key":"B95","doi-asserted-by":"publisher","first-page":"41884","DOI":"10.1038\/s41598-025-25817-4","article-title":"Major histocompatibility class II in murine antigen presenting cells is modified with a branched K63 and K11-linked ubiquitin chain","volume":"15","author":"Liu","year":"2025","journal-title":"Sci Rep"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-024-02438-9","article-title":"Inferring allele-specific copy number aberrations and tumor phylogeography from spatially resolved transcriptomics","volume":"21","author":"Ma","year":"2024","journal-title":"Nat Methods"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: improved peptide-mhc class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010569","article-title":"Leveraging mRNA technology for antigen based immuno-oncology therapies","volume":"13","author":"Floudas","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B99","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cels.2018.05.014","article-title":"MHCflurry: open-source class I MHC binding affinity prediction","volume":"7","author":"O\u2019Donnell","year":"2018","journal-title":"Cell Syst"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1006457","article-title":"Systematically benchmarking peptide-MHC binding predictors: from synthetic to naturally processed epitopes","volume":"14","author":"Zhao","year":"2018","journal-title":"PLoS Comput Biol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/2326-6066.CIR-18-0395","article-title":"High-throughput stability screening of neoantigen\/HLA complexes improves immunogenicity predictions","volume":"7","author":"Blaha","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600582","article-title":"Pan-specific prediction of peptide-MHC class I complex stability, a correlate of T cell immunogenicity","volume":"197","author":"Rasmussen","year":"2016","journal-title":"J Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-021-01310-0","article-title":"Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development","volume":"20","author":"Huang","year":"2021","journal-title":"Mol Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioteChadv.2020.107534","article-title":"The challenge and prospect of mRNA therapeutics landscape","volume":"40","author":"Weng","year":"2020","journal-title":"Biotechnol Adv"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring mRNA vaccine to balance innate\/adaptive immune response","volume":"26","author":"Linares-Fern\u00e1ndez","year":"2020","journal-title":"Trends Mol Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.17","article-title":"Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation","volume":"18","author":"Diken","year":"2011","journal-title":"Gene Ther"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1681","article-title":"A 3\u2032-pre-tRNA-derived small RNA tRF-1-Ser regulated by 25(OH)D promotes proliferation and stemness by inhibiting the function of MBNL1 in breast cancer","volume":"14","author":"Wan","year":"2024","journal-title":"Clin Transl Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2018.08.009","article-title":"The optimization of mRNA expression level by its intrinsic properties\u2014insights from codon usage pattern and structural stability of mRNA","volume":"111","author":"Victor","year":"2019","journal-title":"Genomics"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.13083","article-title":"Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2","volume":"10","author":"Salleh","year":"2022","journal-title":"PeerJ"},{"key":"B110","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.4155\/tde-2016-0006c1","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther Deliv"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-023-00645-2","article-title":"RNA modifications in physiology and disease: towards clinical applications","volume":"25","author":"Delaunay","year":"2024","journal-title":"Nat Rev Genet"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.1c00197","article-title":"Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines","volume":"7","author":"Nance","year":"2021","journal-title":"ACS Cent Sci"},{"key":"B114","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41541-025-01287-7","article-title":"Loop structure in poly(A) tail of mRNA vaccine enhances antigen translation efficiency and mRNA stability","volume":"10","author":"Oh","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13273-021-00171-4","article-title":"Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency","volume":"18","author":"Kim","year":"2022","journal-title":"Mol Cell Toxicol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12951-025-03800-5","article-title":"mRNA vaccines: immunogenicity and quality characteristics","volume":"24","author":"Quan","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3495(00)76552-0","article-title":"Electrostatic control of phospholipid polymorphism","volume":"79","author":"Tarahovsky","year":"2000","journal-title":"Biophys J"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1529\/biophysj.104.042895","article-title":"DNA release from lipoplexes by anionic lipids: correlation with lipid mesomorphism, interfacial curvature, and membrane Fusion","volume":"87","author":"Tarahovsky","year":"2004","journal-title":"Biophys J"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur J Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2014.09.008","article-title":"Prodrug-based nanoparticulate drug delivery strategies for cancer therapy","volume":"35","author":"Luo","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.77","article-title":"Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA","volume":"16","author":"Bonehill","year":"2008","journal-title":"Mol Ther"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114993","article-title":"mRNA: A promising platform for cancer immunotherapy","volume":"199","author":"Kong","year":"2023","journal-title":"Adv Drug Delivery Rev"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000329","article-title":"TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma","volume":"8","author":"De Keersmaecker","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.57","article-title":"Engineering dendritic cells to enhance cancer immunotherapy","volume":"19","author":"Boudreau","year":"2011","journal-title":"Mol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1707654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:16:00Z","timestamp":1770894960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1707654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":124,"alternative-id":["10.3389\/fimmu.2025.1707654"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1707654","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"1707654"}}